Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Net Income | 14.80% | -52.52% | -155.94% | -188.86% | -207.82% |
| Total Depreciation and Amortization | 66.81% | 235.62% | 1,191.49% | 221.54% | 404.35% |
| Total Amortization of Deferred Charges | -1.07% | -26.23% | -50.75% | 52.22% | 22.45% |
| Total Other Non-Cash Items | -72.27% | -26.96% | -2.03% | 201.62% | 2,738.04% |
| Change in Net Operating Assets | 154.98% | 221.22% | 143.02% | 24.23% | -652.86% |
| Cash from Operations | -28.16% | -56.19% | -215.83% | -108.11% | -60.28% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 158.73% | -257.93% | -286.50% | -148.52% | -169.81% |
| Cash from Investing | 158.51% | -259.40% | -287.76% | -148.52% | -169.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 99.55% | 98.05% | 108.13% | 984.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 41.21% | 41.21% | -- | -- |
| Cash from Financing | -100.13% | 99.21% | 97.49% | 88.27% | 910.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -166.22% | -369.83% | -269.08% | -3,700.00% | 131.97% |